DOCSLIB.ORG

No Disclosures

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
No Disclosures 3/15/2017 Cases in Infectious Diseases NO DISCLOSURES Richard A. Jacobs, M.D., PhD. Case Records of the Massachusetts General Hospital Case Presentation A 22 yr old comes to the office complaining of the acute onset of unilateral weakness • Periventricular heterotopia due to an FLNA of the right side of his face. mutation and congenital alveolar dysplasia. Your diagnosis is Bell’s Palsy. N Engl J Med 2017; 376:562‐574 1 3/15/2017 What is Your Therapy? Etiology of Facial Nerve Palsy 100% • 50% are idiopathic (Bell’s Palsy) 1. Prednisolone • Herpes Simplex/Varicella Zoster (Geniculate 2. Acyclovir ganglion) – Direct invasion v. immunologic/inflammatory 3. Prednisolone + • Lyme disease (most common cause of bilateral FN acyclovir palsy) 4. Nothing • Other infections—CMV, EBV,HIV • Non‐infectious—Diabetes, sarcoid, tumors, 1 trauma Therapy of Bell’s Palsy Therapy of Bell’s Palsy • 839 patients enrolled within 72 hours of • Quite controversial onset of symptoms • Because of the association with herpes viruses – Placebo + placebo (206) the use of acyclovir has been felt to be – Prednisilone (60mg X 5 days then reduced beneficial by 10 mg/day) + placebo (210) • – Valacyclovir (1000mg TID X 7 Days) + Two well done prospective, randomized, placebo (207) controlled, blinded studies have been done – Valacyclovir X7 Days + prednisolone X10 Days (206) Lancet Neurol 2008;7:993‐1000 2 3/15/2017 Therapy of Bell’s Palsy Prednisilone Prednisilone • Case closed on therapy??? NO!! + valacyclovir Placebo • Other less powered studies and subgroup Valacyclovir analyses suggest that acyclovir might be + placebo beneficial in the most severe cases – Minimal or no movement of facial muscles and inability to close the eye Take Home Points Case Presentation • 57 yo male with polycystic kidney disease, • Early treatment (within 72 hours of gout, HTN and hyperlipidemia onset) recommended • Underwent bilateral nephrectomies and renal • For most cases prednisolone for 10 days transplant (CMV D +/R‐). Required ATG post‐ is adequate transplant • For severe cases (complete or near • Immunosuppression—mycophenolate 360 mg complete paralysis) prednisolone for 10 BID, tacrolimus 7 mg BID and prednisone 5 mg days + valacyclovir 1000mg TID for 7 days is recommended QD; prophylactic ganciclovir 3 3/15/2017 Case Presentation (cont) Case Presentation (cont) • Shortly after transplant sustained an “injury” • P&SH to his (R) ankle resulting in pain and swelling – Lives in Oakland, CA • About 2 months post‐transplant, at a routine – No travel clinic visit his ankle was warm, red, tender and – No unusual food/animal exposures swollen. • BCs X 2 neg • • WBC‐ 12.5 (4.0‐11.0), CRP‐72 (<6.3) and xray Urine culture‐100,000 CFU of MRSA showed an effusion • Aspiration – Bloody fluid with 102,000 WBCs & 96% PMNs • Admitted for evaluation – Negative for crystals Case Presentation (cont) Case Presentation (cont) • Cultures/stains from aspiration and OR were • The following day he was taken to the OR for I&D all negative for bacteria, fungus and AFB – Chronic appearing inflammation with friable synovium • About one week later, because of failure to • WORKING DIAGNOSIS—transient S. aureus improve, an MRI‐c/w with intraosseous abscesses bacteremia from septic (R) ankle with S. aureus bacteriuria. • Back to the OR – • Started on vancomycin & ceftriaxone pending No gross purulence cultures – “cystic void” in the calcaneus and talus that were opened 4 3/15/2017 Case Presentation (cont) What is your diagnosis? • Cultures for: 1. Gout – Bacteria 2. S. aureus – Fungus 3. Yeast infection (candida) – AFB 4. Mold infection • Additional specialized tests (aspergillus/rhizopus) 5. AFB‐MTb or NTM • 1 week later a diagnosis was made 6. Other University of Washington Molecular Diagnostic Laboratory Can submit tissue, paraffin blocks or sterile fluid DNA sequencing for: UREAPLASMA UREALYTICUM Bacteria (16S ribosomal RNA) Yeast (26S ribosomal RNA) Moulds (28S ribosomal RNA) http://depts.washington.edu/molmicdx/mdx/te sts/bctseq.shtml 5 3/15/2017 Culture Negative Septic Arthritis Culture Negative Septic Arthritis • Prior antibiotics • Sensitivity of the test ( ≈90%) • Reactive arthritis • Lyme disease (Borrelia spp.) – Following diarrhea • Fastidious organisms • Salmonella, Shigella, Campylobacter, Yersinia, C. difficile – Brucella – Coxiella (Q fever) – Following urogenital infections – Legionella • Chlamydia trachomatis – Bartonella – Whipple’s disease – Mycoplasma (immunoglobulin deficiency) Case Presentation Should Prophylaxis Be Given? 100% • The dentist of your 45 year old female patient with MVP and moderate mitral 1.Yes regurgitation calls wanting to know if she needs antibiotic prophylaxis for a root 2.No canal and which one. 1 6 3/15/2017 Prophylaxis for Endocarditis Prophylaxis for Endocarditis • Paradigm shift in recommendations – Lack of published data showing benefit • Original AHA Guidelines in 1997 – Transient bacteremia occurs commonly as a result of normal daily activities • Major revision by AHA in 2007 with several • Brushing and flossing—20%‐68% updates, the most recent in 2014 (J Am Coll • Toothpick—20%‐40% Cardiol. 2014;63(22):e57) • Chewing food—7%‐51% – Endocarditis is more likely to occur from frequent bacteremias associated with daily activities than from bacteremias caused by dental, GI or GU procedures Prophylaxis for Endocarditis High Risk Procedures DENTAL PROCEDURES • Prophylaxis recommended ONLY for: Manipulation of the gingivial tissue: HIGH RISK PROCEDURES ROUTINE DENTAL CLEANING In TOOTH EXTRACTION HIGH RISK INDIVIDUALS Manipulation of the periapical region of the tooth: ROOT CANAL 7 3/15/2017 High Risk Procedures High Risk Procedures RESPIRATORY PROCEDURES SKIN & MUSCULOSKELETAL PROCEDURES Violation of the respiratory mucosa Drainage of an abscess TONSILLECTOMY/ADNOIDECTOMY antibiotics directed at S. aureus and Group A BRONCHOSCOPY WITH BIOPSY streptococcus Drainage of infected material DRAINAGE OF AN EMPYEMA Procedures for Which Endocarditis Conditions of Highest Risk Prophylaxis is NOT Recommended • Included • Not included • GI PROCEDURES – Prosthetic heart valves – Bicuspid aortic valve – Risk of bacteremia low even with biopsy (2%‐5%) – Prior endocarditis – Acquired aortic or mitral valve disease and organisms involved rarely cause endocarditis – Cyanotic heart disease • Unrepaired • MVP with regurgitation • GU PROCEDURES • Partially repaired • Prior valve repair – Risk of bacteremia high with bacteriuria • Repaired within last 6 – Hypertrophic months cardiomyopathy with – TREAT BACTERIURIA BEFORE PROCEDURE – Heart transplant with latent or resting “valvulopathy” obstruction 8 3/15/2017 Back to the Patient Recommended Regimens ( Single Dose 30‐60 min Before Procedure) • She had a high risk procedure—root canal Situation Agent Adult Dose • BUT did NOT have a high risk heart Oral regimen Amoxicillin 2 g Allergic to Cephalexin or 2 g condition—MVP with regurgitation penicillin or Clindamycin 600 mg ampicillin or (minor allergy) Azithromycin/ 500 mg Clarithromycin NO PROHYLAXIS INDICATED Allergic to Clindamycin 600 mg penicillin or or ampicillin Azithromycin/ 500 mg (anaphylaxis, Clarithromycin angioedema or urticaria Case Presentation Should Prophylaxis Be Given? 100% • The dentist of your 65 year old patient who is 9 months s/p total hip 1. Yes arthroplasty calls wanting to know if prophylaxis should be given for a root 2. No canal 1 9 3/15/2017 Dental Prophylaxis for Prosthetic Dental Prophylaxis for Prosthetic Joints Joints—2013 Guidelines • GOOD NEWS • Area of controversy for years between the ADA, AAOS and IDSA – 2004 AAOS & ADA recommendation prophylaxis if joint placed within past 2 years – 2009 AAOS recommends prophylaxis for all prosthetic joints regardless of when placed – Promise of collaboration with joint guidelines – 2013 AAOS & ADA propose new guidelines Dental Prophylaxis for Prosthetic Dental Prophylaxis for Prosthetic Joints—2013 Guidelines Joints—2013 Guidelines • GOOD NEWS • GOOD NEWS – The practitioner might consider discontinuing the – The practitioner might consider discontinuing the practice of routinely prescribing prophylactic practice of routinely prescribing prophylactic antibiotics for patients with hip and knee antibiotics for patients with hip and knee prosthetic joint implants undergoing dental prosthetic joint implants undergoing dental procedures. procedures. • BAD NEWS 10 3/15/2017 Dental Prophylaxis for Prosthetic Dental Prophylaxis for Prosthetic Joints—2013 Guidelines Joints—2013 Guidelines • GOOD NEWS • GOOD NEWS – The practitioner might consider discontinuing the – The practitioner might consider discontinuing the practice of routinely prescribing prophylactic practice of routinely prescribing prophylactic antibiotics for patients with hip and knee prosthetic antibiotics for patients with hip and knee joint implants undergoing dental procedures. prosthetic joint implants undergoing dental • BAD NEWS—> Grade of Recommendation is procedures. Limited • BAD NEWS—> Grade of Recommendation is • Practitioners should be cautious in deciding Limited whether to follow a recommendation classified as Limited What TO DO?? ADA Recommendations • In 2014 the ADA Council on Scientific Affairs • Disconnect between organisms causing PJIs convened an expert panel to clarify the 2013 and mouth flora ADA/AAOS confusing recommendations – Late infections almost always due to skin flora (S. epi, P. acnes, corynebacterium spp) not streptococci found in the mouth • Bacteremias common as a result of everyday activities • Best study cited in the
Load more

Recommended publications
  • Tonsillopharyngitis - Acute (1 of 10)
    Tonsillopharyngitis - Acute (1 of 10) 1 Patient presents w/ sore throat 2 EVALUATION Yes EXPERT Are there signs of REFERRAL complication? No 3 4 EVALUATION Is Group A Beta-hemolytic Yes DIAGNOSIS Streptococcus (GABHS) • Rapid antigen detection test infection suspected? (RADT) • roat culture No TREATMENT EVALUATION No A Supportive management Is GABHS confi rmed? B Pharmacological therapy (Non-GABHS) Yes 5 TREATMENT A EVALUATE RESPONSEMIMS Supportive management TO THERAPY C Pharmacological therapy • Antibiotics Poor/No Good D Surgery, if recurrent or complicated response response REASSESS PATIENT COMPLETE THERAPY & REVIEW THE DIAGNOSIS© Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B269 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (2 of 10) 1 ACUTE TONSILLOPHARYNGITIS • Infl ammation of the tonsils & pharynx • Etiologies include bacterial (group A β-hemolytic streptococcus, Haemophilus infl uenzae, Fusobacterium sp, etc) & viral (infl uenza, adenovirus, coronavirus, rhinovirus, etc) pathogens • Sore throat is the most common presenting symptom in older children TONSILLOPHARYNGITIS 2 EVALUATION FOR COMPLICATIONS • Patients w/ sore throat may have deep neck infections including epiglottitis, peritonsillar or retropharyngeal abscess • Examine for signs of upper airway obstruction Signs & Symptoms of Sore roat w/ Complications • Trismus • Inability to swallow liquids • Increased salivation or drooling • Peritonsillar edema • Deviation of uvula
    [Show full text]
  • Rapid Antigen Detection Test for Group a Streptococcus in Children with Pharyngitis (Review)
    Cochrane Database of Systematic Reviews Rapid antigen detection test for group A streptococcus in children with pharyngitis (Review) Cohen JF, Bertille N, Cohen R, Chalumeau M Cohen JF, Bertille N, Cohen R, Chalumeau M. Rapid antigen detection test for group A streptococcus in children with pharyngitis. Cochrane Database of Systematic Reviews 2016, Issue 7. Art. No.: CD010502. DOI: 10.1002/14651858.CD010502.pub2. www.cochranelibrary.com Rapid antigen detection test for group A streptococcus in children with pharyngitis (Review) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 3 BACKGROUND .................................... 5 OBJECTIVES ..................................... 7 METHODS ...................................... 7 RESULTS....................................... 10 Figure1. ..................................... 11 Figure2. ..................................... 12 Figure3. ..................................... 13 Figure4. ..................................... 15 Figure5. ..................................... 16 Figure6. ..................................... 18 Figure7. ..................................... 20 DISCUSSION ..................................... 21 AUTHORS’CONCLUSIONS . 23 ACKNOWLEDGEMENTS . 23 REFERENCES ..................................... 24 CHARACTERISTICSOFSTUDIES . 42 DATA .......................................
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0136210 A1 Benjamin Et Al
    US 2011013621 OA1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0136210 A1 Benjamin et al. (43) Pub. Date: Jun. 9, 2011 (54) USE OF METHYLSULFONYLMETHANE Publication Classification (MSM) TO MODULATE MICROBIAL ACTIVITY (51) Int. Cl. CI2N 7/06 (2006.01) (75) Inventors: Rodney L. Benjamin, Camas, WA CI2N I/38 (2006.01) (US); Jeffrey Varelman, Moyie (52) U.S. Cl. ......................................... 435/238; 435/244 Springs, ID (US); Anthony L. (57) ABSTRACT Keller, Ashland, OR (US) Disclosed herein are methods of use of methylsulfonyl (73) Assignee: Biogenic Innovations, LLC methane (MSM) to modulate microbial activity, such as to enhance or inhibit the activity of microorganisms. In one (21) Appl. No.: 13/029,001 example, MSM (such as about 0.5% to 5% MSM) is used to enhance fermentation efficiency. Such as to enhance fermen (22) Filed: Feb. 16, 2011 tation efficiency associated with the production of beer, cider, wine, a biofuel, dairy product or any combination thereof. Related U.S. Application Data Also disclosed are in vitro methods for enhancing the growth of one or more probiotic microorganisms and methods of (63) Continuation of application No. PCT/US2010/ enhancing growth of a microorganism in a diagnostic test 054845, filed on Oct. 29, 2010. sample. Methods of inhibiting microbial activity are also disclosed. In one particular example, a method of inhibiting (60) Provisional application No. 61/294,437, filed on Jan. microbial activity includes selecting a medium that is suscep 12, 2010, provisional application No. 61/259,098, tible to H1N1 influenza contamination; and contacting the filed on Nov.
    [Show full text]
  • Swedres-Svarm 2019
    2019 SWEDRES|SVARM Sales of antibiotics and occurrence of antibiotic resistance in Sweden 2 SWEDRES |SVARM 2019 A report on Swedish Antibiotic Sales and Resistance in Human Medicine (Swedres) and Swedish Veterinary Antibiotic Resistance Monitoring (Svarm) Published by: Public Health Agency of Sweden and National Veterinary Institute Editors: Olov Aspevall and Vendela Wiener, Public Health Agency of Sweden Oskar Nilsson and Märit Pringle, National Veterinary Institute Addresses: The Public Health Agency of Sweden Solna. SE-171 82 Solna, Sweden Östersund. Box 505, SE-831 26 Östersund, Sweden Phone: +46 (0) 10 205 20 00 Fax: +46 (0) 8 32 83 30 E-mail: [email protected] www.folkhalsomyndigheten.se National Veterinary Institute SE-751 89 Uppsala, Sweden Phone: +46 (0) 18 67 40 00 Fax: +46 (0) 18 30 91 62 E-mail: [email protected] www.sva.se Text, tables and figures may be cited and reprinted only with reference to this report. Images, photographs and illustrations are protected by copyright. Suggested citation: Swedres-Svarm 2019. Sales of antibiotics and occurrence of resistance in Sweden. Solna/Uppsala ISSN1650-6332 ISSN 1650-6332 Article no. 19088 This title and previous Swedres and Svarm reports are available for downloading at www.folkhalsomyndigheten.se/ Scan the QR code to open Swedres-Svarm 2019 as a pdf in publicerat-material/ or at www.sva.se/swedres-svarm/ your mobile device, for reading and sharing. Use the camera in you’re mobile device or download a free Layout: Dsign Grafisk Form, Helen Eriksson AB QR code reader such as i-nigma in the App Store for Apple Print: Taberg Media Group, Taberg 2020 devices or in Google Play.
    [Show full text]
  • Do Routine Eye Exams Reduce Occurrence of Blindness from Type 2
    JFP_09.04_CI_finalREV 8/25/04 2:22 PM Page 732 Clinical Inquiries F ROM T HE F AMILY P RACTICE I NQUIRIES N ETWORK Do routine eye exams reduce photography. Median follow-up was 3.5 years occurrence of blindness (range, 1–8.5 years). from type 2 diabetes? The patients were divided into cohorts based on level of demonstrated retinopathy. The mean screening interval for a 95% probability of remaining free of sight-threatening retinopathy ■ EVIDENCE-BASED ANSWER was calculated for each grade of baseline Screening eye exams for patients with type 2 retinopathy. Screening patients with no retino- diabetes can detect retinopathy early enough so pathy every 5 years provided a 95% probability of treatment can prevent vision loss. Patients with- remaining free of sight-threatening retinopathy. out diabetic retinopathy who are systematically Patients with background retinopathy must be screened by mydriatic retinal photography have a screened annually to achieve the same result, and 95% probability of remaining free of sight-threat- patients with mild preproliferative retinopathy ening retinopathy over the next 5 years. If back- need to be screened every 4 months (Table). ground or preproliferative retinopathy is found at A systematic review2 of multiple small English- screening (Figure), the 95% probability interval language studies evaluating screening and moni- for remaining free of sight-threatening retino- toring of diabetic retinopathy found consistent pathy is reduced to 12 and 4 months, respective- results. Screening by direct or indirect ophthal- ly (strength of recommendation [SOR]: B, based moscopy alone detected 65% of patients with on 1 prospective cohort study).
    [Show full text]
  • Streptococcal Pharyngitis (Strep Throat)
    Streptococcal Pharyngitis (Strep Throat) Maria Pitaro, MD ore throat is a very common reason for a visit to a health care provider. While the major treatable pathogen is group A beta hemolytic Streptococcus (GAS), Sthis organism is responsible for only 15-30% of sore throat cases in children and 5-10% of cases in adults. Other pathogens that cause sore throat are viruses (about 50%), other bacteria (including Group C beta hemolytic Streptococci and Neisseria gonorrhea), Chlamydia, and Mycoplasma. In this era of increasing microbiologic resistance to antibiotics, the public health goal of all clinicians should be to avoid the inappropriate use of antibiotics and to target treatment to patients most likely to have infection due to GAS. Clinical Manifestations and chest and in the folds of the skin and usually Pharyngitis due to GAS varies in severity. The spares the face, palms, and soles. Flushing of the Streptococcal Pharyngitis most common presentation is an acute illness with cheeks and pallor around the mouth is common, (Strep Throat). sore throat, fever (often >101°F/38.3°C), tonsillar and the tongue becomes swollen, red, and mottled Inflammation of the exudates (pus on the tonsils), and tender cervical (“strawberry tongue”). Both skin and tongue may oropharynx with adenopathy (swollen glands). Patients may also have peel during recovery. petechiae, or small headache, malaise, and anorexia. Additional physical Pharyngitis due to GAS is usually a self-limited red spots, on the soft palate. examination findings may include petechiae of the condition with symptoms resolving in 2-5 days even Photo courtesy soft palate and a red, swollen uvula.
    [Show full text]
  • Sore Throat in Primary Care Project
    Family Practice, 2015, Vol. 32, No. 3, 263–268 doi:10.1093/fampra/cmv015 Advance Access publication 25 March 2015 Epidemiology Sore throat in primary care project: a clinical score to diagnose viral sore throat Selcuk Mistika,*, Selma Gokahmetoglub, Elcin Balcic, and Fahri A Onukd Downloaded from https://academic.oup.com/fampra/article-abstract/32/3/263/695324 by guest on 31 July 2019 aDepartment of Family Medicine, bDepartment of Microbiology, cDepartment of Public Health, Erciyes University Medical Faculty, Kayseri, Turkey, and dBunyamin Somyurek Family Medicine Centre, Kayseri, Turkey. *Correspondence to Prof. S. Mistik, Department of Family Medicine, Erciyes University Medical Faculty, Kayseri 38039, Turkey; E-mail: [email protected] Abstract Objective. Viral agents cause the majority of sore throats. However, there is not currently a score to diagnose viral sore throat. The aims of this study were (i) to find the rate of bacterial and viral causes, (ii) to show the seasonal variations and (iii) to form a new scoring system to diagnose viral sore throat. Methods. A throat culture for group A beta haemolytic streptococci (GABHS) and a nasopharyngeal swab to detect 16 respiratory viruses were obtained from each patient. Over a period of 52 weeks, a total of 624 throat cultures and polymerase chain reaction analyses were performed. Logistic regression analysis was performed to find the clinical score. Results. Viral infection was found in 277 patients (44.3%), and GABHS infection was found in 116 patients (18.5%). An infectious cause was found in 356 patients (57.1%). Rhinovirus was the most commonly detected infectious agent overall (highest in November, 34.5%), and the highest GABHS rate was in November (32.7%).
    [Show full text]
  • Supplemental Content Evaluating Different Strategies for Outpatient
    Supplemental Content Evaluating different strategies for outpatient antimicrobial surveillance Daniel J Livorsi, MD, MSc; Carrie Linn, PharmD, MPH; Bruce Alexander, PharmD; Brett Heintz, PharmD; Traviss Tubbs, PharmD; Eli Perencevich, MD, MS Supplemental Table 1. Diagnostic categories applied to cohort 1 Supplemental Table 2. ICD-10 codes used to identify cases for manual chart review for cohort 2 Supplemental Figures 1-9. Standardized protocols used to assess antimicrobial necessity Supplemental Figure 10. Rates of antimicrobial overtreatment for 6 infectious syndromes in both the Emergency Department and primary care clinics at the Iowa City VA Medical Center Supplemental Table 1. Diagnostic categories applied to cohort 1 Broad category Specific infectious syndromes Acute respiratory tract infections (ARTIs) Acute Bronchitis Influenza Pertussis Pneumonia Upper respiratory tract infection Ear, nose, and throat (ENT) infections Epiglottitis Laryngitis, acute Mastoiditis Otitis externa Otitis media Parotitis, acute bacterial Peri-tonsillar abscess Pharyngitis Tonsillitis Rhinosinusitis, acute or chronic Exacerbations of COPD or asthma Asthma with acute exacerbation COPD with acute exacerbation Gastroenteritis Gastroenteritis, infectious Clostridium difficile-associated diarrhea Genitourinary (GU) Female-specific infections • Bacterial vaginosis • Bartholin’s cyst, infected • Pelvic inflammatory disease • Trichomoniasis • Vulvovaginal candidiasis Male-specific infections • Balanitis • Epididymitis/orchitis • Prostatitis • Urethritis Sexually-transmitted
    [Show full text]
  • Strep Throat -- Familydoctor.Org
    Strep Throat What is strep throat? What are the signs of strep throat? Strep throat is an infection caused by bacteria. It is called "strep" because the bacteria that causes the infection is called streptococcus. Adults with strep throat may have a sore throat, a fever and swollen neck glands. They usually don’t have a cough or a runny nose. Children with strep throat have a sore throat and may have tummy pain or a red rash with small spots. The rash is worse under the arms and in skin creases. How is strep throat treated? Your doctor may give you or your child an antibiotic. Antibiotics kill bacteria, which helps strep throat go away a little faster. It can also prevent a few rare but serious conditions that people with strep throat might get. It is important to take all of the medicine your doctor gives you. Should all sore throats be treated with antibiotics? No. Not every sore throat is strep throat. Bacteria only cause about 5% to 10% of sore throats. The rest are caused by viruses or other problems, and antibiotics will not help. Your doctor can do a test to make sure it is strep throat. What tests can tell I have strep throat? Your doctor may use a test called the rapid strep test. For this test, the doctor uses a long cotton swab to take some material from the back of your throat. The results of this test can be ready in about 15 minutes. Your doctor may also do a culture of the throat material.
    [Show full text]
  • Infectious Disease Control Guideline
    Infectious Disease Control Guideline Government of Nepal Ministry of Health and Population Department of Health Services Epidemiology and Disease Control Division 2073 BS (2016 AD) Infectious Disease Control Guideline Contributors Dr. Baburam Marasini, EDCD Dr. Basudev Pandey, LCD Dr. Guna Nidhi Sharma, EDCD Dr. Ram Raj Panthi, EDCD Mr. Bhim Prasad Sapkota, EDCD Mr. Resham Lal Lamichhane, EDCD Clinical Experts Prof. Dr. Buddha Basnyat, PAHS/OUCRU Prof. Dr. Subesh Raj Kayastha, NAMS Prof. Dr. Sudhamshu KC, NAMS Prof. Dr. Shital Adhikari, CMC Dr. Jitendra Man Shrestha Dr. Vivek Kattel, BPKIHS Dr. Anup Bastola, STIDM Technical Support Mr. Pranaya Kumar Upadhyaya, MOH Dr. Prakash Ghimire, WHO Dr. Keshav Kumar Yogi, WHO Dr. Vivek Dhungana, WHO Dr. Neeta Pokhrel Regmi, WHO Preface Table of Contents Contents Page No. Preface ........................................................................................................................................................... 3 Table of Contents .......................................................................................................................................... 4 Acronyms ....................................................................................................................................................... 7 Chapter I: Introduction .................................................................................................................................. 9 1. Background .......................................................................................................................................
    [Show full text]
  • Infectious Mononucleosis with Staphylococcus Aureus Pharyngitis Co-Infection
    Osteopathic Family Physician (2010) 2, 14-17 Infectious mononucleosis with Staphylococcus aureus pharyngitis co-infection Chad E. Richmond, DO, Mark W. Beyer, OMS IV, BS, Bucky A. Ferozan, OMS IV, BS, Christopher Zipp, DO, MS From the Department of Family Medicine, University of Medicine and Dentistry, Stratford, NJ. KEYWORDS: Summary Epstein-Barr virus (EBV), a member of the herpesvirus family, is one of the most common Infectious human viruses affecting more than 90% of the world’s population. The most common manifestation of mononucleosis; primary infection is a self-limited clinical syndrome that most frequently affects adolescents and young Staphylococcus aureus adults. The incidence of clinical infectious mononucleosis is not well documented because reporting is pharyngitis not obligatory in most states. The available data have been derived from special surveys such as the community survey in Olmstead County, Minnesota, which includes the Mayo Clinic, where a rate of 200 per 100,000 patients had a positive heterophile test.1 Once a diagnosis of mononucleosis is confirmed, treatment is supportive because there is no specific treatment for the disease. Mononucleosis is rarely fatal but some complications include central nervous system involvement, splenic rupture, upper airway obstruction, and bacterial super infections. The following clinical case is of a patient diagnosed with acute infectious mononucleosis with Staphylococcus aureus pharyngitis co-infection. © 2010 Elsevier Inc. All rights reserved. Case presentation Focused physical examination The patient had posterior pharyngeal erythema and exu- History of present illness dates with enlarged tonsils. Enlarged posterior and anterior cervical lymph nodes were also noted. The abdomen was D.D., an 18-year-old female dance student in Philadel- soft with minor nonlocalized tenderness on palpation.
    [Show full text]
  • Pediatrics Rapid Strep Is Enough Modified Centor Criteria
    Pediatrics Probiotics Prevents Diarrhea in Preschool Children • RXT of Healthy children 6 to 36 months attending day care • Lactobacillus reuteri vs. placebo once/day x 3 months with F/U at 6 months • Outcomes: While on the probiotic, ↓ in diarrhea (NNT=6.25); 6 months NNT = 2 • Mean duration of diarrhea ↓ 2.5 days to 1.4 days in first 3 months. In the second three months from 2.4 days to 1.6 days. All statistically significant. • Also Statistically Significant: • ↓ URI in intervenon group in first 3 months (NNT = 8.8) & in second 6 months (NNT = 2.5) • ↓ in days pre‐school missed & a ↓ of 50% of days parents missed of work. • ↓ risk of antibiotic use • There were no adverse events. Pediatrics. 2014: 133(4); e904‐e909. Rapid Strep is Enough Modified Centor Criteria • Systematic review/meta analysis on rapid antigen (RADT) for Group A • Tonsillar exudate or erythema: +1 point strep in Adults & Children w/pharyngitis; 48 studies ~24, 000 patients; • Anterior cervical adenopathy: +1 point culture-reference. • Cough absent: +1 point • Estimate of sensitivity of RADT = 0.86 and specificity = 0.96 • Fever present: +1 point Score • Analysis of studies of just children, sensitivity = 0.87 and specificity = 0.96 • Age 3 to 14 years: +1 point 4 to 5: Treat with antibiotics • Age 15 to 45 years: 0 points • Conclusions: RADTS for GAS high accuracy in both adults and pediatrics 2 to 3: Perform rapid antigen test • Negative RADT sensitive enough to NOT NEED throat culture. • Age over 45 years: -1 points Antigen positive: Treat w/ antibiotics Antigen negative: Throat Culture Antigen negative: Sympt Tx.
    [Show full text]